East Melbourne / Fitzroy / Berlin / Parkville / San Diego / /
Company
Agilent / Elsevier Inc. / Cold Spring Harbor Laboratory / Australia 8Cylene Pharmaceuticals / /
Country
Germany / United States / Australia / /
Currency
pence / / /
Facility
Molecular Biology The University of Melbourne / University of Queensland / Scale bar / University of Melbourne / Hughes Medical Institute / Monash University / Vincent’s Hospital / /
IndustryTerm
Cancer Treatment / rRNA processing / select / treatment of cancer / /
MedicalCondition
few identifiable GFP-tagged tumor / detectable tumor / lymphoma / lymphoma cell lines / B cell lymphoma / wild-type lymphoma cells / Em-Myc lymphoma cell line / human hematologic malignancies / leukemias / large cell immunoblastic lymphoma / Em-Myc lymphoma cell lines / wild-type Em-Myc tumors / Em-Myc tumor / Human Hematological Malignancies / apparent disease / leukemia / tumor / Cancer / tumors / Human leukemia / human hematologic cancer / human cancer / hematologic malignancies / malignant disease / B myelomonocytic leukemia / lymphoma cells / established disease / EmMyc lymphoma cells / Em-Myc lymphoma cell line overexpressing BCL2 / chronic myelogenous leukemia / Em-Myc lymphoma cells / human hematologic cancers / Transplanted p53 Wild-type Em-Myc Lymphoma / aggressive tumors / transplanted EmMyc lymphoma / acute myeloid leukemia / spontaneous lymphoma / /
MedicalTreatment
ccr / /
Organization
University of Melbourne / Therapeutic Administration / Australia 7Victorian Cancer Cytogenetics Service / Monash University / Therapeutic Administration of CX-5461 / St. Vincent’s Hospital / Therapeutic Administration of CX-5461 Increases Survival / University of Queensland / Germany 11Howard Hughes Medical Institute / Cancer Medicine Peter MacCallum Cancer Centre / Australia 3Sir Peter MacCallum Department / /
Person
Megan J. Bywater / Grant A. McArthur / Peter MacCallum / /
Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53